Hitomi Yuki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hitomi Yuki has a total of 229 co-authors. Here are the top co-authors by number of shared publications:
Teruki Honma
RIKEN Center for Integrative Medical Sciences, 1-7-22 Suehiro-Cho, Tsurumi-Ku, Yokohama, Japan
14 shared publications- Teruki Honma
RIKEN Center for Integrative Medical Sciences
12 shared publications Mikako Shirouzu
RIKEN Center for Biosystems Dynamics Research, Tsurumi, Yokohama, Japan
8 shared publicationsAkiko Tanaka
Drug Discovery Structural Biology Platform Unit, RIKEN Center for Life Science Technologies, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan
6 shared publications- Shigeyuki Yokoyama
RIKEN Cluster for Science, Technology and Innovation Hub, Yokohama, Japan
6 shared publications Takehiro Fukami
RIKEN Program for Drug Discovery and Medical Technology Platforms, Yokohama, Japan
5 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by Springer Nature in Nature Communications
- Vol. 17  (1)
GTP hydrolysis by Ras proceeds without a stabilized nucleophilic water molecule
A comprehensive understanding of the Ras self-inactivation mechanism at atomic resolution-specifically, intrinsic GTP hydrolysis converting the GTP-bound active form to the GDP-bound inactive form-is essential for designing therapies against Ras-driven cancers. Conventional models describe a biphasic GTP-bound state: Ras interconverts between inactive state 1 and active, catalytically competent state 2. However, the structural pathway leading to Ras/GDP via these states remains unclear. Here, we use time-resolved serial femtosecond and synchrotron crystallography to capture GTP hydrolysis in Ras crystals loaded with photoactivatable caged GTP, across timescales from milliseconds to hours. Photolysis yielded Ras in state 1-a conformation lacking a stabilized nucleophilic water characteristic of state 2. Remarkably, this state persists for hours and converts directly to Ras/GDP without passing through state 2. These findings challenge the prevailing view that state 2 is essential and suggest that state 1 can directly support catalysis, offering an alternative conceptual basis for targeting clinically relevant Ras mutants that preferentially adopt this conformation.
- 18 November 2026
- Published by Springer Nature in Nature Communications
- Vol. 17  (1)
Open AccessGTP hydrolysis by Ras proceeds without a stabilized nucleophilic water molecule
A comprehensive understanding of the Ras self-inactivation mechanism at atomic resolution-specifically, intrinsic GTP hydrolysis converting the GTP-bound active form to the GDP-bound inactive form-is essential for designing therapies against Ras-driven cancers. Conventional models describe a biphasic GTP-bound state: Ras interconverts between inactive state 1 and active, catalytically competent state 2. However, the structural pathway leading to Ras/GDP via these states remains unclear. Here, we use time-resolved serial femtosecond and synchrotron crystallography to capture GTP hydrolysis in Ras crystals loaded with photoactivatable caged GTP, across timescales from milliseconds to hours. Photolysis yielded Ras in state 1-a conformation lacking a stabilized nucleophilic water characteristic of state 2. Remarkably, this state persists for hours and converts directly to Ras/GDP without passing through state 2. These findings challenge the prevailing view that state 2 is essential and suggest that state 1 can directly support catalysis, offering an alternative conceptual basis for targeting clinically relevant Ras mutants that preferentially adopt this conformation.
- Open Access
- 27 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17  (1) , 8809
Small-molecule RAS/RAF inhibitors target RAS-driven cancers via allosteric RAF disruption
- 27 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17  (1) , 8809
Open AccessSmall-molecule RAS/RAF inhibitors target RAS-driven cancers via allosteric RAF disruption
- Open Access
- 9 February 2026
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 6  (2) , 1400-1410
Data-Driven Design of PROTAC Linkers to Improve PROTAC Cell Membrane Permeability
Proteolysis-targeting chimeras (PROTACs) are promising next-generation therapeutics for the degradation of disease-associated proteins. However, optimizing the physicochemical properties of PROTACs, particularly their poor cell membrane permeability, remains challenging. Traditionally, PROTAC linkers have been manually designed to improve cell membrane permeability. Although recent machine learning-based approaches have enabled the rational design of PROTAC linkers, no linker design methods that explicitly address cell membrane permeability have been reported. In this study, we developed PROTAC-TS, a linker generative model that combines a chemical language model and reinforcement learning to control cell membrane permeability. We first constructed a prediction model of cell membrane permeability, which achieved high prediction performance (R 2 = 0.710). By integrating this prediction model into the generative model, we successfully designed linkers of PROTACs with high predicted cell membrane permeability while considering PROTAC likeness. Our results highlight the potential of PROTAC-TS in accelerating PROTAC development with favorable cell membrane permeability.
- 9 February 2026
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 6  (2) , 1400-1410
Open AccessData-Driven Design of PROTAC Linkers to Improve PROTAC Cell Membrane Permeability
Proteolysis-targeting chimeras (PROTACs) are promising next-generation therapeutics for the degradation of disease-associated proteins. However, optimizing the physicochemical properties of PROTACs, particularly their poor cell membrane permeability, remains challenging. Traditionally, PROTAC linkers have been manually designed to improve cell membrane permeability. Although recent machine learning-based approaches have enabled the rational design of PROTAC linkers, no linker design methods that explicitly address cell membrane permeability have been reported. In this study, we developed PROTAC-TS, a linker generative model that combines a chemical language model and reinforcement learning to control cell membrane permeability. We first constructed a prediction model of cell membrane permeability, which achieved high prediction performance (R 2 = 0.710). By integrating this prediction model into the generative model, we successfully designed linkers of PROTACs with high predicted cell membrane permeability while considering PROTAC likeness. Our results highlight the potential of PROTAC-TS in accelerating PROTAC development with favorable cell membrane permeability.
- Open Access
- 30 August 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Data-driven Design of PROTAC Linkers to Improve PROTAC Cell Membrane Permeability
Proteolysis-targeting chimeras (PROTACs) are promising next-generation therapeutics for the degradation of disease-associated proteins. However, optimizing the physicochemical properties of PROTACs, particularly their poor cell mem-brane permeability, remains challenging. Traditionally, PROTAC linkers have been manually designed to improve cell membrane permeability. Although recent machine learning-based approaches have enabled the rational design of PROTAC linkers, no linker design methods that explicitly address cell membrane permeability have been reported. In this study, we developed PROTAC-TS, a linker generative model that combines a chemical language model and reinforcement learning to control cell membrane permeability. We first constructed a prediction model of cell membrane permeability, which achieved high prediction performance (R2 = 0.710). By integrating this prediction model into the generative model, we successfully designed linkers of PROTACs with high predicted cell membrane permeability while considering PROTAC likeness. Our results highlight the potential of PROTAC-TS in accelerating PROTAC development with favorable cell membrane permea-bility.
- 30 August 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessData-driven Design of PROTAC Linkers to Improve PROTAC Cell Membrane Permeability
Proteolysis-targeting chimeras (PROTACs) are promising next-generation therapeutics for the degradation of disease-associated proteins. However, optimizing the physicochemical properties of PROTACs, particularly their poor cell mem-brane permeability, remains challenging. Traditionally, PROTAC linkers have been manually designed to improve cell membrane permeability. Although recent machine learning-based approaches have enabled the rational design of PROTAC linkers, no linker design methods that explicitly address cell membrane permeability have been reported. In this study, we developed PROTAC-TS, a linker generative model that combines a chemical language model and reinforcement learning to control cell membrane permeability. We first constructed a prediction model of cell membrane permeability, which achieved high prediction performance (R2 = 0.710). By integrating this prediction model into the generative model, we successfully designed linkers of PROTACs with high predicted cell membrane permeability while considering PROTAC likeness. Our results highlight the potential of PROTAC-TS in accelerating PROTAC development with favorable cell membrane permea-bility.
- Open Access
- 23 January 2024
- Published by Springer Nature in Research Square
Small-molecule RAS/RAF Binding Inhibitors Allosterically Disrupt RAF Conformation and Exert Efficacy Against a Broad Spectrum of RAS-driven Cancers
With the advent of approved subtype-specific RAS inhibitors targeting KRASG12C mutation, the development of RAS inhibitors effective regardless of RAS mutation status is the next major challenge to address clinically prevalent RAS mutations and further overcome RAS-driven acquired resistance to currently available drugs. Here our multi-module drug screening for compounds capable of RAS/RAF-binding inhibition, and subsequent structural study discovered small-molecule compounds which covalently bind to a unique site in the regulatory domain of RAF, and disrupt RAF conformation allosterically, thereby preventing RAS/RAF-interaction and downstream signals. The compounds exhibit anti-tumor efficacy to multiple cancer types with broad-spectrum RAS mutations including clinically predominant G12D and G12V KRAS, NRAS and HRAS in pre-clinical models. Furthermore, the compounds effectively suppress tumor growth of BRAFV600E-melanoma with acquired resistance to RAF kinase inhibitor. Collectively, our study provides effectiveness for designing RAF-targeting drugs, and potentially therapeutic RAS/RAF-signaling inhibitors with novel mechanism to overcome broad-range RAS-driven cancers.
- 23 January 2024
- Published by Springer Nature in Research Square
Open AccessSmall-molecule RAS/RAF Binding Inhibitors Allosterically Disrupt RAF Conformation and Exert Efficacy Against a Broad Spectrum of RAS-driven Cancers
With the advent of approved subtype-specific RAS inhibitors targeting KRASG12C mutation, the development of RAS inhibitors effective regardless of RAS mutation status is the next major challenge to address clinically prevalent RAS mutations and further overcome RAS-driven acquired resistance to currently available drugs. Here our multi-module drug screening for compounds capable of RAS/RAF-binding inhibition, and subsequent structural study discovered small-molecule compounds which covalently bind to a unique site in the regulatory domain of RAF, and disrupt RAF conformation allosterically, thereby preventing RAS/RAF-interaction and downstream signals. The compounds exhibit anti-tumor efficacy to multiple cancer types with broad-spectrum RAS mutations including clinically predominant G12D and G12V KRAS, NRAS and HRAS in pre-clinical models. Furthermore, the compounds effectively suppress tumor growth of BRAFV600E-melanoma with acquired resistance to RAF kinase inhibitor. Collectively, our study provides effectiveness for designing RAF-targeting drugs, and potentially therapeutic RAS/RAF-signaling inhibitors with novel mechanism to overcome broad-range RAS-driven cancers.
- 6 April 2023
- Published by American Chemical Society (ACS) in The Journal of Physical Chemistry Letters
- Vol. 14  (15) , 3609-3620
Quantum Chemical Interaction Analysis between SARS-CoV-2 Main Protease and Ensitrelvir Compared with Its Initial Screening Hit
- 6 April 2023
- Published by American Chemical Society (ACS) in The Journal of Physical Chemistry Letters
- Vol. 14  (15) , 3609-3620
Quantum Chemical Interaction Analysis between SARS-CoV-2 Main Protease and Ensitrelvir Compared with Its Initial Screening Hit
- Open Access
- 21 December 2022
- Published by Springer Nature in Nature Communications
- Vol. 13  (1) , 1
Author Correction: Identifying antibiotics based on structural differences in the conserved allostery from mitochondrial heme-copper oxidases
- 21 December 2022
- Published by Springer Nature in Nature Communications
- Vol. 13  (1) , 1
Open AccessAuthor Correction: Identifying antibiotics based on structural differences in the conserved allostery from mitochondrial heme-copper oxidases
- Open Access
- 8 December 2022
- Published by Springer Nature in Nature Communications
- Vol. 13  (1) , 1-14
Identifying antibiotics based on structural differences in the conserved allostery from mitochondrial heme-copper oxidases
Antimicrobial resistance (AMR) is a global health problem. Despite the enormous efforts made in the last decade, threats from some species, including drug-resistant Neisseria gonorrhoeae, continue to rise and would become untreatable. The development of antibiotics with a different mechanism of action is seriously required. Here, we identified an allosteric inhibitory site buried inside eukaryotic mitochondrial heme-copper oxidases (HCOs), the essential respiratory enzymes for life. The steric conformation around the binding pocket of HCOs is highly conserved among bacteria and eukaryotes, yet the latter has an extra helix. This structural difference in the conserved allostery enabled us to rationally identify bacterial HCO-specific inhibitors: an antibiotic compound against ceftriaxone-resistant Neisseria gonorrhoeae. Molecular dynamics combined with resonance Raman spectroscopy and stopped-flow spectroscopy revealed an allosteric obstruction in the substrate accessing channel as a mechanism of inhibition. Our approach opens fresh avenues in modulating protein functions and broadens our options to overcome AMR.
- 8 December 2022
- Published by Springer Nature in Nature Communications
- Vol. 13  (1) , 1-14
Open AccessIdentifying antibiotics based on structural differences in the conserved allostery from mitochondrial heme-copper oxidases
Antimicrobial resistance (AMR) is a global health problem. Despite the enormous efforts made in the last decade, threats from some species, including drug-resistant Neisseria gonorrhoeae, continue to rise and would become untreatable. The development of antibiotics with a different mechanism of action is seriously required. Here, we identified an allosteric inhibitory site buried inside eukaryotic mitochondrial heme-copper oxidases (HCOs), the essential respiratory enzymes for life. The steric conformation around the binding pocket of HCOs is highly conserved among bacteria and eukaryotes, yet the latter has an extra helix. This structural difference in the conserved allostery enabled us to rationally identify bacterial HCO-specific inhibitors: an antibiotic compound against ceftriaxone-resistant Neisseria gonorrhoeae. Molecular dynamics combined with resonance Raman spectroscopy and stopped-flow spectroscopy revealed an allosteric obstruction in the substrate accessing channel as a mechanism of inhibition. Our approach opens fresh avenues in modulating protein functions and broadens our options to overcome AMR.
- 18 March 2021
- Published by Springer Nature in Nature Cancer
- Vol. 2  (3) , 340-356
Combined inhibition of XIAP and BCL2 drives maximal therapeutic efficacy in genetically diverse aggressive acute myeloid leukemia
Aggressive therapy-resistant and refractory acute myeloid leukemia (AML) has an extremely poor outcome. By analyzing a large number of genetically complex and diverse, primary high-risk poor-outcome human AML samples, we identified specific pathways of therapeutic vulnerability. Through drug screens followed by extensive in vivo validation and genomic analyses, we found inhibition of cytosolic and mitochondrial anti-apoptotic proteins XIAP, BCL2 and MCL1, and a key regulator of mitosis, AURKB, as a vulnerability hub based on patient-specific genetic aberrations and transcriptional signatures. Combinatorial therapeutic inhibition of XIAP with an additional patient-specific vulnerability eliminated established AML in vivo in patient-derived xenografts (PDXs) bearing diverse genetic aberrations, with no signs of recurrence during off-treatment follow-up. By integrating genomic profiling and drug-sensitivity testing, this work provides a platform for a precision-medicine approach for treating aggressive AML with high unmet need.
- 18 March 2021
- Published by Springer Nature in Nature Cancer
- Vol. 2  (3) , 340-356
Combined inhibition of XIAP and BCL2 drives maximal therapeutic efficacy in genetically diverse aggressive acute myeloid leukemia
Aggressive therapy-resistant and refractory acute myeloid leukemia (AML) has an extremely poor outcome. By analyzing a large number of genetically complex and diverse, primary high-risk poor-outcome human AML samples, we identified specific pathways of therapeutic vulnerability. Through drug screens followed by extensive in vivo validation and genomic analyses, we found inhibition of cytosolic and mitochondrial anti-apoptotic proteins XIAP, BCL2 and MCL1, and a key regulator of mitosis, AURKB, as a vulnerability hub based on patient-specific genetic aberrations and transcriptional signatures. Combinatorial therapeutic inhibition of XIAP with an additional patient-specific vulnerability eliminated established AML in vivo in patient-derived xenografts (PDXs) bearing diverse genetic aberrations, with no signs of recurrence during off-treatment follow-up. By integrating genomic profiling and drug-sensitivity testing, this work provides a platform for a precision-medicine approach for treating aggressive AML with high unmet need.
- Open Access
- 4 February 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16  (2) , e0243855
The ubiquinone synthesis pathway is a promising drug target for Chagas disease
Chagas disease is caused by infection with the protozoan parasite Trypanosoma cruzi (T. cruzi). It was originally a Latin American endemic health problem, but now is expanding worldwide as a result of increasing migration. The currently available drugs for Chagas disease, benznidazole and nifurtimox, provoke severe adverse effects, and thus the development of new drugs is urgently required. Ubiquinone (UQ) is essential for respiratory chain and redox balance in trypanosomatid protozoans, therefore we aimed to provide evidence that inhibitors of the UQ biosynthesis have trypanocidal activities. In this study, inhibitors of the human COQ7, a key enzyme of the UQ synthesis, were tested for their trypanocidal activities because they were expected to cross-react and inhibit trypanosomal COQ7 due to their genetic homology. We show the trypanocidal activity of a newly found human COQ7 inhibitor, an oxazinoquinoline derivative. The structurally similar compounds were selected from the commercially available compounds by 2D and 3D ligand-based similarity searches. Among 38 compounds selected, 12 compounds with the oxazinoquinoline structure inhibited significantly the growth of epimastigotes of T. cruzi. The most effective 3 compounds also showed the significant antitrypanosomal activity against the mammalian stage of T. cruzi at lower concentrations than benznidazole, a commonly used drug today. We found that epimastigotes treated with the inhibitor contained reduced levels of UQ9. Further, the growth of epimastigotes treated with the inhibitors was partially rescued by UQ10 supplementation to the culture medium. These results suggest that the antitrypanosomal mechanism of the oxazinoquinoline derivatives results from inhibition of the trypanosomal UQ synthesis leading to a shortage of the UQ pool. Our data indicate that the UQ synthesis pathway of T. cruzi is a promising drug target for Chagas disease.
- 4 February 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16  (2) , e0243855
Open AccessThe ubiquinone synthesis pathway is a promising drug target for Chagas disease
Chagas disease is caused by infection with the protozoan parasite Trypanosoma cruzi (T. cruzi). It was originally a Latin American endemic health problem, but now is expanding worldwide as a result of increasing migration. The currently available drugs for Chagas disease, benznidazole and nifurtimox, provoke severe adverse effects, and thus the development of new drugs is urgently required. Ubiquinone (UQ) is essential for respiratory chain and redox balance in trypanosomatid protozoans, therefore we aimed to provide evidence that inhibitors of the UQ biosynthesis have trypanocidal activities. In this study, inhibitors of the human COQ7, a key enzyme of the UQ synthesis, were tested for their trypanocidal activities because they were expected to cross-react and inhibit trypanosomal COQ7 due to their genetic homology. We show the trypanocidal activity of a newly found human COQ7 inhibitor, an oxazinoquinoline derivative. The structurally similar compounds were selected from the commercially available compounds by 2D and 3D ligand-based similarity searches. Among 38 compounds selected, 12 compounds with the oxazinoquinoline structure inhibited significantly the growth of epimastigotes of T. cruzi. The most effective 3 compounds also showed the significant antitrypanosomal activity against the mammalian stage of T. cruzi at lower concentrations than benznidazole, a commonly used drug today. We found that epimastigotes treated with the inhibitor contained reduced levels of UQ9. Further, the growth of epimastigotes treated with the inhibitors was partially rescued by UQ10 supplementation to the culture medium. These results suggest that the antitrypanosomal mechanism of the oxazinoquinoline derivatives results from inhibition of the trypanosomal UQ synthesis leading to a shortage of the UQ pool. Our data indicate that the UQ synthesis pathway of T. cruzi is a promising drug target for Chagas disease.